This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.
OBJECTIVES To determine the effect of growth hormone ( GH ) on body composition and motor development in infants and toddlers with Prader-Willi syndrome ( PWS ) . STUDY DESIGN Twenty-nine subjects with PWS ( 4 - 37 months of age ) were r and omized to GH treatment ( 1mg/m 2 /day ) or observation for 12 months . Percent body fat , lean body mass , and bone mineral density were measured by dual x-ray absorptiometry ; energy expenditure was measured by deuterium dilution ; and motor constructs of mobility ( M ) and stability ( S ) were assessed using the Toddler Infant Motor Evaluation ( TIME ) . RESULTS GH-treated subjects , compared with controls , demonstrated decreased percent body fat ( mean , 22.6 % + /- 8.9 % vs 28.5 % + /- 7.9 % ; P < .001 ) , increased lean body mass ( mean , 9.82 + /- 1.9 kg vs 6.3 + /- 1.9 kg ; P < .001 ) , and increased height velocity Z scores ( mean , 5 . 0 + /- 1.8 vs 1.4 + /- 1.0 ; P < .001 ) . Patients who began GH before 18 months of age showed higher mobility skill acquisition compared with controls within the same age range ( mean increase in raw score , 284 + /- 105 vs 206 + /- 63 ; P < .05 ) . CONCLUSIONS GH treatment of infants and toddlers with PWS for 12 months significantly improves body composition and when begun before 18 months of age increases mobility skill acquisition . These results suggest that GH therapy instituted early in life may lessen deterioration of body composition in PWS while also accelerating motor development
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .